News | Wearables | September 09, 2015

SRI International Licenses DataSpeaks Software for Virtual Clinical Decision-Making

DataSpeaks' proprietary algorithm can generate scores suggesting dose adjustments and medication switches via patient-generated and sensor data

 

DataSpeaks, SRI International, license, SIMA, clinical decision support

September 9, 2015 — SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.

The SIMA algorithm can transform multiple streams of patient-generated and sensor data (from wearable or implantable devices) into actionable, integrated, and personalized assessments of risks (harms) and benefits for drugs in a patient's regimen. The resulting scores may be used in the future to quickly alert healthcare practitioners about potential needs for dose adjustments and medication switches.

"The unique SIMA analytic software has the capacity to synergize with other SRI platforms as a component of an integrated enterprise system designed to enhance clinical decision-making, thereby maximizing the likelihood of treatment benefit and minimizing the risk of significant side-effects related to drugs," said David Sahner, M.D., senior director, clinical translation, SRI Biosciences. "This offers the hope of major reductions in morbidity, mortality and the over $7 billion in annual healthcare costs related to the use of potentially inappropriate medications."

The in-licensing of the software was enabled by a grant from the Michigan Economic Development Corporation to establish an inter-institutional Center of Innovation focused on personalized medicine and pharmacotherapy in the elderly.

DataSpeaks' proprietary SIMA algorithm applies to multivariate time series data that are becoming ubiquitous with hospital, home, wearable, implanted, and environmental monitoring devices; apps; electronic diaries; and pill monitors. SIMA yields internally standardized scores that quantify evidence for clinically relevant interactions over time as "edges" in network graphs that are computed from data about individual patients.

Additional potential uses of SIMA include improvement of diagnostic taxonomies that may facilitate better prediction and therapy choices, identification of disease mechanisms and new drug development targets, and use in novel clinical trial designs that do not "wash out" individual patient differences.

For more information: www.dataspeaks.com, www.sri.com

Related Content

Necklace Patient Monitor Detects Abnormal Heart Rhythm. An necklace has been developed that detects abnormal heart rhythm will be showcased for the first time on EHRA Essentials 4 You, a scientific platform of the European Society of Cardiology (ESC). This wearable necklace ECG monitor provides a new and easy method for detecting an abnormal heart rhythm called atrial fibrillation and is accurate, according to a new study from the University of Eastern Finland.

This wearable necklace ECG monitor provides a new and easy method for detecting an abnormal heart rhythm called atrial fibrillation and is accurate, according to a new study from the University of Eastern Finland.

News | Wearables | May 08, 2020
May 2020 — An necklace has been developed that detects abnormal heart rhythm will be showcased for the first time on
Videos | Wearables | January 09, 2020
The Consumer Electronic Show (CES) is the world's gathering place for consumer technologies, with more than 175,000...
AliveCor's KardiaMobile six-lead ECG system that works on smartphone platforms. It was cleared in 2019 and includes artificial intelligence algorithms to help identify arrhythmias.

AliveCor's KardiaMobile six-lead ECG system that works on smartphone platforms. It was cleared in 2019 and includes artificial intelligence algorithms to help identify arrhythmias. 

News | Wearables | October 31, 2019
October 31, 2019 — AliveCor, a provider of smartphone based ECG technology and Huami Corp., a provider of biometric,
Fitbit trackers could help detect atrial fibrillation
News | Wearables | October 17, 2019
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are...
Bardy Diagnostics Selected for HealthTech Arkansas Accelerator Program
News | Wearables | August 15, 2019
Bardy Diagnostics Inc. announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects...
Bardy Diagnostics Wins MedTech Breakthrough Award for Best New Diagnostic Technology
News | Wearables | June 14, 2019
Bardy Diagnostics Inc. announced that its Carnation Ambulatory Monitor (CAM) was recognized with the “Best New...
Apple Heart Study Demonstrates Ability of Wearable Technology to Detect Atrial Fibrillation
News | Wearables | March 18, 2019
Researchers from the Stanford University School of Medicine presented preliminary results of the Apple Heart Study, a...